Methods This meta-analysis included individual participant data from 22 trials of statin versus control (n=134 537; mean LDL cholesterol diff erence 1·08 mmol/L; median follow-up 4·8 years) and fi ve trials of more versus less statin (n=39 612; diff erence 0·51 mmol/L; 5·1 years). Major vascular events were major coronary events (ie, non-fatal myocardial infarction or coronary death), strokes, or coronary revascularisations. Participants were separated into fi ve categories of baseline 5-year major vascular event risk on control therapy (no statin or low-intensity statin) (<5%, ≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in each, the rate ratio (RR) per 1·0 mmol/L LDL cholesterol reduction was estimated.
Introduction
The Cholesterol Treatment Trialists' (CTT) Collaboration previously reported meta-analyses of individual data from 170 000 individuals in 21 trials of standard statin regimens versus control and fi ve trials of more intensive versus less intensive regimens. 1 That report showed that lowering of LDL cholesterol by 1 mmol/L with a standard statin regimen reduced the incidence of major vascular events (defi ned as non-fatal myocardial infarction or coronary death, any stroke, or coronary revascularisation procedure) by around a fi fth, and that further reductions in LDL cholesterol with more intensive statin regimens yielded further reductions in risk. There was no evidence that lowering of LDL cholesterol increased the risk of non-vascular death or of cancer, even in participants with baseline LDL cholesterol less than 2 mmol/L (in whom LDL cholesterol was reduced from about 1·7 mmol/L [65 mg/dL] to 1·3 mmol/L [50 mg/dL]). 2 In those analyses, reduction of LDL cholesterol with a statin in participants with no previous history of vascular disease reduced the risk of major vascular events by about a fi fth, 1 but there remains uncertainty about whether statin therapy is of overall net benefi t in primary prevention. [3] [4] [5] This question is important because, although individuals without previous vascular disease are at lower absolute risk, at least half of all vascular events occur among them. 6 The availability of individual participant data from each trial within the CTT database (allowing the inclusion of information from both primary prevention trials and low-risk participants in other trials) allows a more complete assessment of the eff ects of lowering of LDL cholesterol in low-risk people than was possible in previous metaanalyses of published data. 3, 4 Median predicted 5 
Methods

Trials
The methods of the CTT collaboration have been described in detail elsewhere. 1, 7, 8 In the present analyses, a trial was eligible if it reported by the end of 2009 and provided data before June, 2011, and met three criteria: (1) it included at least one intervention whose main eff ect was to lower LDL cholesterol concentration; (2) it was unconfounded with respect to this intervention (ie, no other diff erences in risk factor modifi cation between the treatment groups were intended); and (3) it recruited at least 1000 participants with scheduled treatment duration of at least 2 years. The main outcomes of interest were major vascular events, major coronary events (defi ned as non-fatal myocardial infarction or coronary death), stroke (subdivided by type), coronary revascularisation pro cedures, cancers, and cause-specifi c mortality.
Statistical analysis
Two diff erent Cox proportional hazards models were developed to allow risk to be modelled separately in trials of statin versus control (22 trials; model 1) and in trials of more versus less intensive statin regimens (fi ve trials; model 2). Both models incorporated terms derived from characteristics measured at the time of randomisation, terms that modelled average diff erences in risk between trials (as well as within specifi c periods of time within each trial), and interaction terms (appendix pp 1-2). On the basis of these risk prediction models, participants in both treatment groups of each study were assigned to one of fi ve baseline categories of 5-year risk of a major vascular event: <5%; ≥5% to <10%; ≥10% to <20%; ≥20% to <30%; or ≥30%. Further details of model development are shown in the appendix pp 15-16. Analyses included all participants who were randomly assigned to treatment groups, irrespective of whether they received their allocated treatment (ie, intention-totreat). Analyses of the eff ects on disease rates within each trial are derived from the logrank (o-e) statistic and its variance (v) for fi rst events. Meta-analyses were weighted by the absolute LDL cholesterol diff erence in that trial at 1 year (d mmol/L), and are reported as eff ects per 1·0 mmol/L reduction in LDL cholesterol. In a metaanalysis of several trials, the log of the rate ratio (RR) per 1·0 mmol/L was calculated as S/V with variance 1/V (and hence, for example, with 95% CI of S/V±1·96/√V), where S is the sum over all trials of d(o-e) and V is the sum over all trials of d²v. For most subgroup analyses, the weight for a particular subgroup was the LDL cholesterol diff erence observed in the whole trial, but analyses by baseline LDL cholesterol concentration used LDL weights specifi c to a particular subgroup of a particular trial. 1 In trials comparing more versus less intensive statin therapy, the relevant baseline lipid values were those achieved on the less intensive regimen. In three of these trials, [9] [10] [11] however, any statin therapy was stopped before randomisation, so we estimated their relevant baseline values by multiplying the values at the randomisation visit (ie, off statin treatment) by the mean proportional reduction CHD=coronary heart disease. MCE=major coronary event. *Estimated using standard Kaplan-Meier methods with participants censored at their date of death; median follow-up and baseline LDL cholesterol for trial subgroups weighted by trial subgroup-specifi c variances of observed logrank (o-e) for major vascular events. †History of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, peripheral artery disease or heart failure (if known). ‡No known history of CHD or other vascular disease. §The estimated 5-year major vascular event risk is with the less intensive statin regimen and observed MVE and MCE rates are for participants allocated the less intensive statin regimen; in three more versus less statin trials (A to Z, PROVE-IT, and IDEAL) there was no active run-in period before randomisation and so for the purpose of risk stratifi cation and presentation of results the LDL cholesterol at baseline for the participants in these trials was adjusted for the observed LDL cholesterol reduction from baseline to year 1 in those allocated low intensity statin in the respective trial. ¶Includes 141 participants (48 [4 MVEs] from A to Z and 93 [11 MVEs] from SEARCH) with an estimated 5-year risk of MVE between 5% and 10%. 
Number of participants
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Results
Individual participant data were available from 27 trials in 174 149 participants. 22 trials compared a standard statin regimen versus control (134 537 participants; mean baseline LDL cholesterol 3·70 [SD 0·7] mmol/L; mean diff erence at 1 year 1·08 mmol/L; median follow-up duration in survivors 4·8 years) and fi ve trials assessed a more intensive versus a less intensive statin regimen (39 612 participants; mean baseline LDL cholesterol 2·53 [SD 0·6] mmol/L; mean diff erence at 1 year 0·51 mmol/L; median follow-up duration in survivors 5·1 years). [9] [10] [11] 34, 35 Individual participant data were unavailable from only two eligible trials in 6331 higher-risk patients with pre-existing vascular disease (SPARCL 36 and GREACE 37 ). The baseline prognostic factors that were strong predictors of major vascular event risk (ie, at the 1% signifi cance level) were broadly similar in the trials of statin versus control and the trials of more versus less intensive statin regimens (appendix pp 1-2). Predicted risk compared well with observed risk for each trial, as well as within each 5-year risk group (appendix p 3). When trials were ordered by their median 5-year predicted risk of a major vascular event, the fi ve trials with the lowest median predicted risks (all <10%) were primary prevention trials (table 1) . 13, 15, 22, 29, 31 By contrast, almost all participants with predicted 5-year risk of 20% or higher were recruited into trials in patients with a defi nite history of vascular disease. 12, 14, [16] [17] [18] [19] 25, 28 The predicted 5-year risk of a major vascular event was also 20% or higher in most dialysis patients. 26, 30 In two trials in patients with heart failure, 32, 33 there was a high risk of sudden death, but such deaths were categorised diff erently, with a much smaller proportion of such deaths thought to be due to coronary occlusion in the GISSI-HF trial 33 than in CORONA; 32 this diff erence is the main reason why the predicted 5-year risk of major vascular events was more than twice as high in CORONA (23%) as in GISSI-HF (10%).
Among the 22 trials of statin versus control, the observed annual major vascular event rate ranged from 0·6% in the lowest predicted risk category to 9·5% in the highest risk category, whereas in trials of more versus less intensive statin therapy (which were undertaken solely in patients with previous coronary disease) the observed annual event rate varied between 3·7% and 10·7% across the categories studied (table 2). In both sets of trials, the achieved reduction in LDL cholesterol at 1 year with statin therapy or more intensive statin therapy was greater in people with higher predicted 5-year risk of major vascular events (appendix p 4).
Among all 27 trials, statins reduced the risk of major vascular events by 21% per 1·0 mmol/L LDL cholesterol reduction (RR 0·79, 95% CI 0·77-0·81, p<0·0001), with separately signifi cant proportional reductions in each risk group (fi gure 1). In particular, there were signifi cant reductions in major vascular event risk in each of the two 
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Trend test
Statin/more Control/less 
5-year MVE risk at baseline
Coronary revascularisation <5% ≥5% to <10% ≥10% to <20% ≥20% to <30%
≥30%
Overall For more on R see www.R-project.org lowest risk categories (RR per 1·0 mmol/L LDL cholesterol reduction 0·62, 99% CI 0·47-0·81, for 5-year predicted risk <5%, and 0·69, 99% CI 0·60-0·79, for 5-year predicted risk ≥5% to <10%; both p<0·0001; fi gure 1). These results were qualitatively similar after exclusion of fi ve trials 12, 15, 22, 24, 31 that ended early on the advice of their data monitoring committees (data not shown). The proportional reductions in major vascular events per 1·0 mmol/L LDL cholesterol reduction in the two lowest risk categories seemed to be at least as large as for other participants (fi gure 1), even after further stratifi cation by age and sex (appendix p 6) or by baseline LDL cholesterol (appendix p 7).
The reductions in risk of major vascular events among the two categories of participant at lowest risk refl ected reductions in major coronary events (RR per 1·0 mmol/L LDL cholesterol reduction 0·57, 99% CI 0·36-0·89, p=0·0012, and 0·61, 99% CI 0·50-0·74, p<0·0001), mainly non-fatal myocardial infarction, and in coronary revascularisations (RR 0·52, 99% CI 0·35-0·75, and 0·63, 99% CI 0·51-0·79; both p<0·0001), that were at least as large as those seen in higher risk participants (trend p=0·02 for major coronary events and p=0·03 for coronary revascularisations; fi gure 1, appendix p 8). The reduction in stroke risk per 1·0 mmol/L LDL cholesterol reduction (RR 0·85, 95% CI 0·80-0·89) was similar at all levels of baseline major vascular event risk (trend p=0·3; fi gure 1). In particular, the reduction in stroke risk in those with predicted 5-year major vascular event risk lower than 10% (ie, the two lowest risk groups combined; RR 0·76, 99% CI 0·61-0·95; p=0·0012) was similar to that seen in higher risk categories. The proportional reductions in ischaemic stroke (RR per 1·0 mmol/L LDL cholesterol reduction 0·79, 95% CI 0·74-0·85) and in strokes of unknown cause (RR 0·87, 95% CI 0·79-0·97) were similar irrespective of baseline major vascular event risk, and there was no evidence that the RR for haemorrhagic stroke (1·15, 95% CI 0·97-1·38) varied by baseline risk (appendix p 9). Separate analyses of major vascular events and its components in the trials that tested statin versus control and the trials that tested more versus less intensive statin regimens are shown in the appendix pp 10-11.
For participants with previous vascular disease, the proportional reductions in major vascular event risk were broadly similar irrespective of predicted risk of these events (fi gure 2). In participants with no history of vascular disease, the proportional reduction in major vascular events was at least as large in the two lowest risk groups (RR per 1·0 mmol/L LDL reduction 0·61, 99% CI 0·45-0·81, and 0·66, 99% CI 0·57-0·77) as in those at higher risk. Further exclusion from these lowest risk groups of participants with diabetes or chronic kidney disease had little eff ect on the proportional reductions in major vascular events (RR per 1·0 mmol/L LDL cholesterol reduction 0·63, 99% CI 0·46-0·85, for 5-year predicted risk <5%; 0·64, 99% CI 0·54-0·76, for 5-year predicted risk ≥5% to <10%). The LDL-weighted proportional reduction in major coronary events in participants with no history of vascular disease was also at least as large in the two lowest risk groups as in those at higher risk (appendix p 12).
In all participants, there was a proportional reduction in vascular mortality of 12% per 1·0 mmol/L LDL cholesterol reduction (RR 0·88, 95% CI 0·84-0·91; fi gure 3), which was chiefl y attributable to reductions in coronary deaths of 20% (RR 0·80, 95% CI 0·76-0·85) and in other cardiac deaths of 8% (RR 0·92, 95% CI 0·87-0·98; appendix p 13). There were too few deaths among the lower risk participants to allow reliable direct assessment of the eff ects of statin therapy (appendix p 13). However, the LDL-weighted proportional reductions seemed similar in each risk category both for the aggregate of all vascular deaths (trend p=0·7; fi gure 3) and for each specifi c cause of vascular death (all trend p=NS; appendix p 13), and there was no signifi cant trend towards an increase in non-vascular mortality in those at lower risk (trend p=0·9; fi gure 3). In participants with no history of vascular disease, reduction of LDL cholesterol with statin therapy reduced the risk of 
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Figure 2: Eff ects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol at diff erent levels of risk, by history of vascular disease
MVE=major vascular event. RR=rate ratio. CI=confi dence interval.
vascular mortality (RR per 1·0 mmol/L reduction 0·85, 95% CI 0·77-0·95, p=0·004; fi gure 3) and, since there was no increase in the risk of non-vascular causes of death (RR 0·97, 95% CI 0·88-1·07; fi gure 3), reduced the risk of all-cause mortality (RR 0·91, 95% CI 0·85-0·97, p=0·007; appendix p 14). These mortality benefi ts remained even after further exclusion of participants with diabetes or chronic kidney disease at baseline (vascular death, RR 0·80, 95% CI 0·67-0·95; any death, 0·87, 95% CI 0·78-0·95). There was no evidence of an increase in cancer incidence (RR per 1·0 mmol/L LDL reduction 1·00, 95% CI 0·96-1·04) or of cancer death (RR 0·99, 95% CI 0·93-1·06) at any level of major vascular event risk (fi gure 4).
Discussion
The most recent CTT meta-analysis of individual participant data from randomised trials showed that lowering of LDL cholesterol with standard statin regimens safely reduced the 5-year incidence of major coronary events, coronary revascularisations, and ischaemic strokes by about one fi fth per 1·0 mmol/L reduction in LDL cholesterol, and that additional reductions in LDL cholesterol obtained with more intensive statin regimens further reduced the incidence of these major vascular events. 1 The present results show that reduction of LDL cholesterol with statin therapy signifi cantly reduced the risk of major vascular events in individuals with 5-year risk lower than 10% (in whom the mean risks were 2·6% for major coronary events plus 3% for other major vascular events), even in those with no previous history of vascular disease, diabetes, or chronic kidney disease (panel). The estimated absolute reduction in major vascular events in participants with 5-year risk of these events lower than 10% was around 11 per 1000 over 5 years for each 1·0 mmol/L reduction in LDL cholesterol (4·1% statin or more intensive statin regimen vs 5·2% control or less intensive regimen). Modern statin regimens, however, can often reduce LDL cholesterol by more than 1 mmol/L, 38, 39 which would yield even larger absolute reductions in major vascular events. The avoidance of life-threatening or potentially disabling events in apparently healthy low-risk people might be deemed worthwhile provided that they are not accompanied by any defi nite hazard that is of comparable severity. Although there was no evidence of any increased risk of death from non-vascular causes or of cancer in those at low risk (which is consistent with previous detailed analyses of the eff ect of statins on cancer 2 ), several known 
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Figure 3: Eff ects on vascular and non-vascular deaths per 1·0 mmol/L reduction in LDL cholesterol at diff erent levels of risk, by history of vascular disease
MVE=major vascular event. RR=rate ratio. CI=confi dence interval. There were a further 179 (statin/more statin) versus 210 (control/less statin) deaths of unknown cause among participants without vascular disease and 309 (statin/ more statin) versus 338 (control/less statin) deaths of unknown cause among participants with vascular disease.
or potential hazards of statin therapy need to be considered when estimating the net eff ects of statin therapy in people at lowest risk. First, statin therapy is associated with a small increased risk of myopathy (excess incidence of about 0·5 per 1000 over 5 years) and, more rarely, of rhabdomyolysis (excess incidence of about 0·1 per 1000 over 5 years). 38 The risks of myopathy are dose-related but, with the exception of simvastatin 80 mg daily (or lower doses in Asian populations), intensive statin regimens have not been shown to result in substantial myopathy risks. 38 Second, the most recent CTT report raised the possibility that statin therapy might increase the risk of haemorrhagic stroke. 1 The present analyses suggest that the annual excess risk of haemorrhagic strokes per 1·0 mmol/L LDL cholesterol reduction might be of the order of 0·5 per 1000 people treated over 5 years (appendix p 9), although it might be higher in populations in which haemorrhagic stroke accounts for a higher proportion of strokes (eg, Asian populations 40 ). But, since statin therapy produced a clear reduction in overall stroke that was independent of predicted risk, such an increase in haemorrhagic stroke risk would typically be outweighed by the reduction in the risk of ischaemic stroke (as well as the reduction in other occlusive vascular events and deaths) even in individuals whose 5-year risk of major vascular events is lower than 5%. Third, recent meta-analyses have suggested that statin therapy might be associated with a proportional increase in the diagnosis of diabetes mellitus of about 10% 41 and that more intensive statin therapy produces a bigger increase. 42 The observed incidence of diabetes recorded in the primary prevention trials was about 5% over 5 years, so the absolute excess was about 0·1% per year. 41 If new diagnoses of diabetes were associated with an immediate doubling in cardiovascular risk 43 in individuals with 5-year risk of major vascular events lower than 10%, then the expected eff ect would be only about 0·2 fewer events avoided per 1000 individuals treated over 5 years. Such an eff ect is more than 50-times smaller than the absolute benefi t observed with statin therapy in such individuals (about 11 fewer major vascular events per 1000 treated over 5 years per 1·0 mmol/L reduction in LDL cholesterol; see fi gure 5 for absolute benefi ts corresponding to particular reductions in LDL cholesterol in individuals at diff erent levels of major vascular event risk). Moreover, long-term follow-up of statin trials has shown that the absolute reductions in major vascular events increase while the statin treatment is continued 1 and that these benefi ts persist for at least 5 years after the treatment has stopped, with no evidence of any adverse eff ects emerging with extended follow-up. [44] [45] [46] [47] These fi ndings would suggest that any long-term eff ects of any small excesses in haemorrhagic strokes and in diagnoses of diabetes are not associated with long-term eff ects on major vascular events that are suffi ciently large to outweigh the persistent benefi ts of statin therapy.
The observed event rates shown in the fi gures for each risk category can be readily compared with risk thresholds used in treatment guidelines. For example, under present guidelines, including those of the Adult Treatment Panel III, 48, 49 
Panel: Research in context
Systematic review
Lowering of LDL cholesterol with a statin reduces the risk of myocardial infarction, coronary death, ischaemic stroke, and coronary revascularisation by about one fi fth per 1 mmol/L LDL cholesterol reduction in a wide range of people. 1 However, tabular meta-analyses of people at low risk of these events, studied predominantly in primary prevention trials, have concluded that statin therapy might not result in worthwhile net benefi t in this group. 3, 4 Interpretation Individual participant data in the Cholesterol Treatment Trialists' Collaboration of 27 trials involving 175 000 participants showed that statin therapy reduces the risk of major vascular events (non-fatal myocardial infarction, coronary death, coronary revascularisation, or stroke) in people with 5-year risk of such an event lower than 10% (and, separately, in those at 5-year risk <5%), and in these people each 1·0 mmol/L reduction in LDL cholesterol produces 11 fewer major vascular events per 1000 treated over 5 years, a benefi t that greatly exceeds any known hazards of statin therapy.
Society, 51 and the UK National Institute of Clinical Excellence, 52 people with 5-year risk of major vascular events lower than 10% (ie, the lowest two categories of risk in these analyses) would typically not be judged suitable for statin treatment (table 3, appendix p 5). Judgments about the appropriateness of widespread prescription of statins for the primary prevention of vascular events in patients at lower risk also depend on the cost eff ectiveness of such a strategy, which in turn depends on the local availability and cost of therapy. Generic statin interventions, if eff ective, are likely to be cost-eff ective in individuals at annual vascular disease risk down to at least about 1%. [53] [54] [55] The present report shows that statins are indeed both eff ective and safe for people with 5-year risk of major vascular events lower than 10% and, therefore, suggests that these guidelines might need to be reconsidered.
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